Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action.[2][3] The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.[2]
History
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.[4][5]
In April 2016, the company announced a name change from Arrowhead Research Corporation to Arrowhead Pharmaceuticals, Inc.[6]
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead's ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[7]
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[8]
Products
The company has sixteen products in its pipeline, in various stages of development.[2]
External links
References
- Arrowhead Pharmaceuticals Reports Fiscal 2025 Year End Results November 25, 2025^
- arwr-10q_20170331.htm www.sec.gov, retrieved 2017-05-17^
- 8-K www.sec.gov, retrieved 2017-05-17^
- Arrowhead buys Novartis' RNAi portfolio Reuters, 2017-03-05, retrieved 2017-05-17^
- Staff. Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement Genetic Engineering & Biotechnology News, 1 April 2015^
- Arrowhead Research Changes Name to Arrowhead Pharmaceuticals www.businesswire.com, 2016-04-06, retrieved 2020-04-06^
- Amgen, Arrowhead team up on gene-therapies for heart disease Reuters, 2017-09-29, retrieved 2017-05-17^
- Arrowhead Enters $3.7 Billion License and Collaboration Marketwatch, 2018-10-04, retrieved 2018-10-04^